

Demystifying the Science Behind Targeted Treatments and Immunotherapies for Malignant Melanoma

Virtual study day

Thursday 8 July 2021

Event ID 856

Aims:

This morning's content builds on the virtual study day presented by Dr Vickers on 03 & 04 December: "Molecular mechanisms of targeted treatments and immunotherapies for solid tumours".

The aim of this course is to provide an up-to-date overview of modern systemic treatment approaches given to people with malignant melanoma. Including treatment combinations and new approaches currently being investigated in clinical trials.

Dr Vickers' goal is to explain the science that underpins each treatment. She also hopes to provide learners with a broad understanding of why treatments work well for some patients but not for others.

Elaine's presentations are full of colourful and enlightening illustrations to help learners make sense of scientific concepts. Her descriptions avoid unnecessary jargon and are pitched so that even those with a limited understanding of cell biology are able to understand.

Audience:

This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with solid tumours, and to junior doctors.

Cost:

£50 per delegate

Register:

www.royalmarsden.nhs.uk/studydays

Get in touch:

Conferenceteam@rmh.nhs.uk

020 7808 2921



Follow us:



Programme

- 10:00** **Welcome and Introductions**
- 10:10** **Session 1—Biology and Genetics of Malignant Melanoma**
- Cell of origin and mechanisms of development
 - Key genetic mutations in malignant melanoma cells
 - Differences between melanomas on sun-exposed vs non-sun exposed skin and between cutaneous and non-cutaneous melanomas
 - Melanoma and the immune system – a dynamic relationship
- 10:45** **Live Q&A**
- 10:55** **Break/Sponsor Exhibition**
- 11:00** **Session 2—B-Raf and MEK Inhibitors**
- Refresher of growth factor receptor signalling pathways and the normal functions of B-Raf and MEK
 - Licensed B-Raf & MEK inhibitors; summary of pivotal trials
 - Resistance mechanisms to B-Raf /MEK inhibitors
 - Recent trial data and the path ahead
 - Other actionable mutations and biomarkers
- 11:35** **Live Q&A**
- 11:45** **Break/Sponsor Exhibition**
- 11:50** **Session 3—Immunotherapy for Malignant Melanoma**
- Refresher of checkpoint inhibitor mechanism of action
 - Why checkpoint inhibitors often work well against melanoma, and why they sometimes don't
 - Licensed checkpoint inhibitors; summary of pivotal trials
 - Recent trial data and the path ahead
 - Novel immunotherapies in trials
- 12:25** **Live Q&A**

Please note that the content will be available for 30 days after the event online.

Sponsors:



Pierre Fabre

The above sponsors provided funding for the study day, but they have had no input into the programme, selection of speakers or topics.